Palash Samanta1, Cornelius J Clancy2,3, Rachel V Marini4, Ryan M Rivosecchi4, Erin K McCreary4, Ryan K Shields2,4, Bonnie A Falcione4, Alex Viehman1, Lauren Sacha4, Eun Jeong Kwak1, Fernanda P Silveira1,2, Pablo G Sanchez2,5, Matthew Morrell2,6, Lloyd Clarke4, M Hong Nguyen1,2. 1. Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 2. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 3. Division of Infectious Diseases, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA. 4. Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 5. Department of Cardiothoracic Surgery, Division of Lung Transplantation and Lung Failure, University of Pittsburgh Medical Center, Pennsylvania, USA. 6. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND: Invasive fungal infections (IFIs) are common following lung transplantation. Isavuconazole is unstudied as prophylaxis in organ transplant recipients. We compared effectiveness and tolerability of isavuconazole and voriconazole prophylaxis in lung transplant recipients. METHODS: A single-center, retrospective study of patients who received isavuconazole (September 2015-February 2018) or voriconazole (September 2013-September 2015) for antifungal prophylaxis. IFIs were defined by EORTC/MSG criteria. RESULTS: Patients received isavuconazole (n = 144) or voriconazole (n = 156) for median 3.4 and 3.1 months, respectively. Adjunctive inhaled amphotericin B (iAmB) was administered to 100% and 41% of patients in the respective groups. At 1 year, 8% of patients receiving isavuconazole or voriconazole developed IFIs. For both groups, 70% and 30% of IFIs were caused by molds and yeasts, respectively, and breakthrough IFI (bIFI) rate was 3%. Outcomes did not significantly differ for patients receiving or not receiving iAmB. Independent risk factors for bIFI and breakthrough invasive mold infection (bIMI) were mold-positive respiratory culture and red blood cell transfusion >7 units at transplant. Bronchial necrosis >2 cm from anastomosis and basiliximab induction were also independent risk factors for bIMI. Isavuconazole and voriconazole were discontinued prematurely due to adverse events in 11% and 36% of patients, respectively (P = .0001). Most common causes of voriconazole and isavuconazole discontinuation were hepatotoxicity and lack of oral intake, respectively. Patients receiving ≥90 days prophylaxis had fewer IFIs at 1 year (3% vs 9%, P = .02). IFIs were associated with increased mortality (P = .0001) and longer hospitalizations (P = .0005). CONCLUSIONS: Isavuconazole was effective and well tolerated as antifungal prophylaxis following lung transplantation.
BACKGROUND:Invasive fungal infections (IFIs) are common following lung transplantation. Isavuconazole is unstudied as prophylaxis in organ transplant recipients. We compared effectiveness and tolerability of isavuconazole and voriconazole prophylaxis in lung transplant recipients. METHODS: A single-center, retrospective study of patients who received isavuconazole (September 2015-February 2018) or voriconazole (September 2013-September 2015) for antifungal prophylaxis. IFIs were defined by EORTC/MSG criteria. RESULTS:Patients received isavuconazole (n = 144) or voriconazole (n = 156) for median 3.4 and 3.1 months, respectively. Adjunctive inhaled amphotericin B (iAmB) was administered to 100% and 41% of patients in the respective groups. At 1 year, 8% of patients receiving isavuconazole or voriconazole developed IFIs. For both groups, 70% and 30% of IFIs were caused by molds and yeasts, respectively, and breakthrough IFI (bIFI) rate was 3%. Outcomes did not significantly differ for patients receiving or not receiving iAmB. Independent risk factors for bIFI and breakthrough invasive mold infection (bIMI) were mold-positive respiratory culture and red blood cell transfusion >7 units at transplant. Bronchial necrosis >2 cm from anastomosis and basiliximab induction were also independent risk factors for bIMI. Isavuconazole and voriconazole were discontinued prematurely due to adverse events in 11% and 36% of patients, respectively (P = .0001). Most common causes of voriconazole and isavuconazole discontinuation were hepatotoxicity and lack of oral intake, respectively. Patients receiving ≥90 days prophylaxis had fewer IFIs at 1 year (3% vs 9%, P = .02). IFIs were associated with increased mortality (P = .0001) and longer hospitalizations (P = .0005). CONCLUSIONS:Isavuconazole was effective and well tolerated as antifungal prophylaxis following lung transplantation.
Authors: Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez Journal: N Engl J Med Date: 2007-01-25 Impact factor: 91.245
Authors: Meagan L Adamsick; Ramy H Elshaboury; Thais Gift; Michael K Mansour; Camille N Kotton; Ronak G Gandhi Journal: Transpl Infect Dis Date: 2019-01-29 Impact factor: 2.228
Authors: Dimitra Mitsani; M Hong Nguyen; Ryan K Shields; Yoshiya Toyoda; Eun J Kwak; Fernanda P Silveira; Joseph M Pilewski; Maria M Crespo; Christian Bermudez; Jay K Bhama; Cornelius J Clancy Journal: Antimicrob Agents Chemother Date: 2012-02-13 Impact factor: 5.191
Authors: Lauren Fontana; David S Perlin; Yanan Zhao; Brie N Noble; James S Lewis; Lynne Strasfeld; Morgan Hakki Journal: Clin Infect Dis Date: 2020-02-14 Impact factor: 9.079
Authors: Dimitrios P Kontoyiannis; Dominik Selleslag; Kathleen Mullane; Oliver A Cornely; William Hope; Olivier Lortholary; Rodney Croos-Dabrera; Christopher Lademacher; Marc Engelhardt; Thomas F Patterson Journal: J Antimicrob Chemother Date: 2018-03-01 Impact factor: 5.790
Authors: Amit V Desai; Laura L Kovanda; William W Hope; David Andes; Johan W Mouton; Donna L Kowalski; Robert W Townsend; Salim Mujais; Peter L Bonate Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: James S Lewis; Nathan P Wiederhold; Morgan Hakki; George R Thompson Journal: Antimicrob Agents Chemother Date: 2022-08-15 Impact factor: 5.938